Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their Tumors

New England Journal of Medicine

Volumn 327, Issue 17, 1992, Pages 1209-1215

  Kwak, Larry W ^a   Campbell, Michael J ^a   Czerwinski, Debra K ^a   Hart, Sarah ^a   Miller, Richard A ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN IDIOTYPE;

ADULT; ANTIGEN BINDING; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOMA CELL; MALE; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; AUTOANTIGENS; CLONE CELLS; FEMALE; HUMAN; IMMUNITY, CELLULAR; IMMUNOGLOBULIN IDIOTYPES; IMMUNOGLOBULINS, SURFACE; LYMPHOMA, B-CELL; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0026793994     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199210223271705     Document Type: Article

References (28)

1. Stevenson GT, Stevenson FK. Antibody to molecularly-defined antigen confined to a tumor cell surface. Nature 1975; 254: 714–6.
2. Stevenson GT, Elliott EV, Stevenson FK. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed Proc 1977; 36: 2268–71.
3. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982: 306: 517–22.
4. Meeker TC, Lowder J, Maloney DG, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349–63.
5. Brown SL, Miller TA, Horning SJ, et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651–61.
6. Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci U S A 1971: 68: 3130–5.
7. Jørgensen T, Gaudernack G, Hannestad K. Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315. Scand J Immunol 1980; 11: 29–35.
8. Daley MJ, Gebel HM, Lynch RG. Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy. J Immunol 1978; 120: 1620–4.
9. Bridges SH. Participation of the humoral immune system in the myeloma-specific transplantation resistance. J Immunol 1978; 121: 479–83.
10. Freedman PM, Autry JR, Tokuda S, Williams RC Jr. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J Natl Cancer Inst 1976; 56: 735–40.
11. Sugai S, Palmer DW, Talal N, Witz IP. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice. J Exp Med 1974; 140: 1547–58.
12. Stevenson FK, Gordon J. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J Immunol 1983; 130: 970–3.
13. George AJT, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in the suppression of a mouse B cell lymphoma, BCL1. J Immunol 1987; 138: 628–34.
14. Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotype vaccination against murine B cell lymphoma: inhibition of tumor immunity by free idiotype protein. J Immunol 1987; 138: 1289–96.
15. Campbell MJ, Carroll W, Kon S, et al. Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987; 139: 2825–33.
16. Campbell MJ, Esserman L, Byars NE, Allison achéal, Levy R. Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990; 145: 1029–36.
17. George AJT, Folkard SG, Hamblin TJ, Stevenson FK. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 1988; 141: 2168–74.
18. Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma: combination of idiotype immunization and cyclophosphamide. J Immunol 1988; 141: 3227–33.
19. Campbell MJ, Esserman L, Byars NE, Allison achéal, Levy R. Development of a new therapeutic approach to B cell malignancy: the induction of immunity by the host against cell surface receptor on the tumor. Int Rev Immunol 1989; 4: 251–70.
20. Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 1986; 89: 61–72.
21. Allison achéal, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods 1986; 95: 157–68.
22. Chain B, McCafferty I, Wallace G, Askenase PW. Improvement of the in vitro T cell proliferation assay by a modified method that separates the antigen recognition and IL-2-dependent steps. J Immunol Methods 1987; 99: 221–8.
23. Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 1985; 312: 1658–65.
24. Hoover HC Jr, Surdyke MG, Dangel RB, Peters LC, Hanna MG Jr. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 1985; 55: 1236–43.
25. Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 1988; 61: 1065–70.
26. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8: 1858–67.
27. Mitchell MS, Harel W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990; 8: 856–69.
28. Hoon DS, Foshag LJ, Nizze AS, Bohman R, Morton DL. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 1990; 50: 5358–64.